AIM ImmunoTech Inc. (AIM)
AIM Stock Price Chart
Explore AIM ImmunoTech Inc. interactive price chart. Choose custom timeframes to analyze AIM price movements and trends.
AIM Company Profile
Discover essential business fundamentals and corporate details for AIM ImmunoTech Inc. (AIM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Jul 1996
Employees
21.00
Website
https://www.aimimmuno.comCEO
Thomas K. Equels
Description
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
AIM Financial Timeline
Browse a chronological timeline of AIM ImmunoTech Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Nov 2025
EPS estimate is -$8.00.
Earnings released on 14 Aug 2025
EPS came in at -$3.68 surpassing the estimated -$8.00 by +54.00%, while revenue for the quarter reached $25.00K , missing expectations by -75.00%.
Stock split effective on 12 Jun 2025
Shares were split 1 : 100 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 15 May 2025
EPS came in at -$5.00 surpassing the estimated -$8.00 by +37.50%, while revenue for the quarter reached $16.00K .
Earnings released on 27 Mar 2025
EPS came in at -$10.00 falling short of the estimated -$9.00 by -11.11%, while revenue for the quarter reached $45.00K , missing expectations by -55.00%.
Earnings released on 14 Nov 2024
EPS came in at -$6.00 surpassing the estimated -$10.00 by +40.00%, while revenue for the quarter reached $35.00K , missing expectations by -65.00%.
Earnings released on 14 Aug 2024
EPS came in at -$3.00 falling short of the estimated -$0.12 by -2.40K%, while revenue for the quarter reached $50.00K , beating expectations by +400.00%.
Earnings released on 16 May 2024
EPS came in at -$12.00 falling short of the estimated -$0.11 by -10.81K%, while revenue for the quarter reached $40.00K .
Earnings released on 29 Mar 2024
EPS came in at -$26.00 falling short of the estimated -$0.15 by -17.23K%, while revenue for the quarter reached $65.00K , beating expectations by +62.50%.
Earnings released on 14 Nov 2023
EPS came in at -$16.00 falling short of the estimated -$0.11 by -14.45K%, while revenue for the quarter reached $46.00K , beating expectations by +15.00%.
Earnings released on 15 Aug 2023
EPS came in at -$10.00 falling short of the estimated -$0.11 by -8.99K%, while revenue for the quarter reached $42.00K , beating expectations by +110.00%.
Earnings released on 12 May 2023
EPS came in at -$8.00 falling short of the estimated -$0.11 by -7.17K%, while revenue for the quarter reached $49.00K .
Earnings released on 3 Apr 2023
EPS came in at -$9.00 falling short of the estimated -$0.12 by -7.40K%, while revenue for the quarter reached $56.00K , missing expectations by -68.89%.
Earnings released on 15 Nov 2022
EPS came in at -$13.00 falling short of the estimated -$0.08 by -16.15K%, while revenue for the quarter reached $21.00K , missing expectations by -88.33%.
Earnings released on 15 Aug 2022
EPS came in at -$10.00 falling short of the estimated -$0.07 by -14.19K%, while revenue for the quarter reached $30.00K , missing expectations by -78.21%.
Earnings released on 16 May 2022
EPS came in at -$8.00 falling short of the estimated -$0.07 by -11.33K%, while revenue for the quarter reached $33.00K , missing expectations by -67.00%.
Earnings released on 31 Mar 2022
EPS came in at -$12.00 falling short of the estimated -$0.08 by -14.90K%, while revenue for the quarter reached $50.00K , beating expectations by +36.36%.
Earnings released on 16 Nov 2021
EPS came in at -$8.00 falling short of the estimated -$0.07 by -11.33K%, while revenue for the quarter reached $33.00K , missing expectations by -90.57%.
Earnings released on 17 Aug 2021
EPS came in at -$12.00 , while revenue for the quarter reached $23.00K , missing expectations by -93.43%.
Earnings released on 18 May 2021
EPS came in at -$8.00 falling short of the estimated -$0.09 by -8.79K%, while revenue for the quarter reached $28.00K , missing expectations by -10.00%.
Earnings released on 31 Mar 2021
EPS came in at -$9.00 falling short of the estimated -$0.07 by -12.76K%, while revenue for the quarter reached $42.00K .
Earnings released on 13 Nov 2020
EPS came in at -$8.00 falling short of the estimated -$0.08 by -9.90K%, while revenue for the quarter reached $36.00K , meeting expectations.
AIM Stock Performance
Access detailed AIM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.